```
L104          1 S 172732-61-5/RN

     FILE 'CAPLUS' ENTERED AT 17:12:21 ON 09 NOV 2001
L105         15 S L104

     FILE 'REGISTRY' ENTERED AT 17:12:22 ON 09 NOV 2001
L106          1 S 172732-60-4/RN

     FILE 'CAPLUS' ENTERED AT 17:12:22 ON 09 NOV 2001
L107         18 S L106
L108         34 S L107 OR L105 OR L103 OR L101 OR L99 OR L97 OR L95 OR L93 OR
L

=> d l108 ibib abs it 1-34

L108 ANSWER 1 OF 34  CAPLUS  COPYRIGHT 2001 ACS
ACCESSION NUMBER:         2001:676601  CAPLUS
DOCUMENT NUMBER:          135:236446
TITLE:                    Compositions containing potential secretory
                          phospholipase A2 (sPLA2) inhibitors for the treatment
                          of pain
INVENTOR(S):              Macias, William Louis
PATENT ASSIGNEE(S):       Eli Lilly and Company, USA
SOURCE:                   PCT Int. Appl., 196 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2001066111      A1   20010913       WO 2001-US9      20010116
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                  US 2000-188135   P  20000309
OTHER SOURCE(S):          MARPAT 135:236446
AB   A method is disclosed for the treatment of pain by administering to an
     animal in need thereof a therapeutically effective amt. of a sPLA2
     inhibitor, e.g. a 1H-indole-3-glyoxylamide or sPLA2 inhibitor in
     combination with propoxyphene.  Prepn. of [(3-(2-Amino-1,2-dioxoethyl)-2-
     ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy]acetic acid is described.
IT   Drug delivery systems
        (aerosols; secretory phospholipase A2 inhibitors for treatment of
pain)
IT   Drug delivery systems
        (capsules; secretory phospholipase A2 inhibitors for treatment of
pain)
IT   Drug delivery systems
        (injections, i.m.; secretory phospholipase A2 inhibitors for treatment
        of pain)
IT   Drug delivery systems
        (injections, i.v.; secretory phospholipase A2 inhibitors for treatment
```

of pain)
IT Drug delivery systems
(injections; secretory phospholipase A2 inhibitors for treatment of pain)
IT Drug delivery systems
(nasal sprays; secretory phospholipase A2 inhibitors for treatment of pain)
IT Drug delivery systems
(oral; secretory phospholipase A2 inhibitors for treatment of pain)
IT Drug delivery systems
(parenterals; secretory phospholipase A2 inhibitors for treatment of pain)
IT Drug delivery systems
(prodrugs; secretory phospholipase A2 inhibitors for treatment of pain)
IT Analgesics
Drug delivery systems
(secretory phospholipase A2 inhibitors for treatment of pain)
IT Drug delivery systems
(suspensions; secretory phospholipase A2 inhibitors for treatment of pain)
IT Drug delivery systems
(tablets; secretory phospholipase A2 inhibitors for treatment of pain)
IT Drug delivery systems
(transdermal; secretory phospholipase A2 inhibitors for treatment of pain)
IT 164082-78-4P 164082-79-5P, 2-Ethyl-4-methoxy-1H-indole 164082-80-8P
172733-06-1P 220862-18-0P 220862-19-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction; secretory phospholipase A2 inhibitors for treatment of pain)
IT 100-39-0, Benzyl bromide 598-30-1, sec-Butyllithium 38857-88-4
104863-65-2, N-Methoxy-N-methylpropanamide 164082-77-3
RL: RCT (Reactant)
(reaction; secretory phospholipase A2 inhibitors for treatment of pain)
IT 172733-08-3
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(secretory phospholipase A2 inhibitors for treatment of pain)
IT **172732-68-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(secretory phospholipase A2 inhibitors for treatment of pain)
IT 50-78-2, Aspirin 86-74-8, Carbazole 86-74-8D, 9H-Carbazole, derivs.
103-81-1, Benzeneacetamide 103-90-2, Acetaminophen 109-97-7, Pyrrole
109-97-7D, Pyrrole, derivs. 274-45-3D, Pyrrolo[1,2-a]pyrazine, derivs.
288-13-1, Pyrazole 288-13-1D, Pyrazole, derivs. 469-62-5, Propoxyphene
469-62-5D, Propoxyphene, isomers 879-37-8, 1H-Indole-3-acetamide
1639-60-7, Darvon 2243-81-4, Naphthyl acetamide 5548-10-7
5548-10-7D, derivs. 7505-92-2 7505-92-2D, derivs. 19402-87-0,
9-Benzylcarbazole 19402-87-0D, derivs. 22204-53-1, Naproxen
30524-86-8, Tetrahydrocarbazole 30524-86-8D, Tetrahydrocarbazole, derivs. 39597-63-2, 1H-Indole-1-acetamide 166251-27-0,
Indene-1-acetamide 166251-27-0D, Indene-1-acetamide, derivs.
172732-60-4 172732-60-4D, derivs. **172732-61-5**
172732-61-5D, derivs. **172732-62-6 172732-62-6D**

, derivs. **172732-63-7 172732-63-7D**, derivs. **172732-64-8 172732-64-8D**, derivs. **172732-65-9 172732-65-9D**, derivs. **172732-66-0 172732-66-0D**, derivs. **172732-67-1 172732-67-1D**, derivs. **172732-68-2D**, derivs. **172732-69-3 172732-69-3D**, derivs. **172732-70-6 172732-70-6D**, derivs. **172732-71-7 172732-71-7D**, derivs. **172732-72-8 172732-72-8D**, derivs. 172732-73-9 172732-73-9D, derivs. 172732-74-0 172732-74-0D, derivs. 172733-42-5 207340-63-4 207340-64-5 207340-65-6 207340-67-8 207340-68-9 207340-69-0 207340-70-3 207340-71-4 207340-72-5 207340-73-6 215160-61-5 245756-90-5 245757-22-6 245757-60-2 245757-62-4 245757-66-8 245757-68-0 245757-70-4 245757-72-6 352352-73-9 352352-74-0 352352-75-1 352352-76-2, Indolizine-1-acetamide 352352-77-3, Indolizine-1-acetic acid hydrazide 352352-78-4 352352-79-5 352352-80-8 352352-80-8D, derivs. 359841-74-0 359841-74-0D, derivs.
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(secretory phospholipase A2 inhibitors for treatment of pain)

IT 9001-84-7, Phospholipase A2
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(secretory phospholipase A2 inhibitors for treatment of pain)

REFERENCE COUNT: 3
REFERENCE(S): (1) Beight, D; WO 0069818 A 2000
(2) Lin, H; WO 0105761 A 2001 CAPLUS
(3) Mihelich, E; WO 0007591 A 2000 CAPLUS

L108 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:676600 CAPLUS
DOCUMENT NUMBER: 135:236432
TITLE: Methods and formulations containing secretory phospholipase A2 (sPLA2) inhibitors for the treatment of renal dysfunction
INVENTOR(S): Macias, William Louis; Meador, Vincent Phillip
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066110	A2	20010913	WO 2001-US7	20010116

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-188039 P 20000309
OTHER SOURCE(S): MARPAT 135:236432

AB A method is disclosed for the treatment of symptoms assocd. with renal dysfunction by administering to an animal in need thereof a therapeutically effective amt. of a sPLA2 inhibitor, e.g. a

1H-indole-3-glyoxylamide. Prepn. of [(3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy]acetic acid is described.

IT Drug delivery systems
(aerosols; secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT Drug delivery systems
(capsules; secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT Salts, biological studies
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(drugs for restoration of salt and water balance; secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT Kidney, disease
(failure, acute; secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT Kidney, disease
(failure, chronic; secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT Drug delivery systems
(injections; secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT Drug delivery systems
(nasal sprays; secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT Drug delivery systems
(oral; secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT Drug delivery systems
(parenterals; secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT Drug delivery systems
(prodrugs; secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT Dialysis
Drug delivery systems
Erythropoiesis
Kidney, disease
(secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT Toxins
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT Drug delivery systems
(suspensions; secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT Drug delivery systems
(tablets; secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT 7732-18-5, Water, biological studies
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(drugs for restoration of salt and water balance; secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT 164082-78-4P 164082-79-5P, 2-Ethyl-4-methoxy-1H-indole 164082-80-8P
172733-06-1P 220862-18-0P 220862-19-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction; secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT 100-39-0, Benzyl bromide 598-30-1, sec-Butyllithium 38857-88-4
104863-65-2, N-Methoxy-N-methylpropanamide 164082-77-3
RL: RCT (Reactant)
(reaction; secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT 140608-64-6, OKT 3
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT 86-74-8, Carbazole 86-74-8D, 9H-Carbazole, derivs. 103-81-1, Benzeneacetamide 109-97-7, Pyrrole 109-97-7D, Pyrrole, derivs. 274-45-3D, Pyrrolo[1,2-a]pyrazine, derivs. 288-13-1, Pyrazole 288-13-1D, Pyrazole, derivs. 879-37-8, 1H-Indole-3-acetamide 2243-81-4, Naphthyl acetamide 5548-10-7 5548-10-7D, derivs. 7505-92-2 7505-92-2D, derivs. 11096-26-7, Erythropoietin 19402-87-0,
9-Benzylcarbazole 30524-86-8, Tetrahydrocarbazole 30524-86-8D, Tetrahydrocarbazole, derivs. 39597-63-2, 1H-Indole-1-acetamide 85637-73-6, Atrial natriuretic factor 166251-27-0, Indene-1-acetamide 166251-27-0D, Indene-1-acetamide, derivs. **172732-60-4 172732-60-4D**, derivs. **172732-61-5 172732-61-5D**, derivs. **172732-62-6 172732-62-6D**, derivs. **172732-63-7 172732-63-7D**, derivs. **172732-64-8 172732-64-8D**, derivs. **172732-65-9 172732-65-9D**, derivs. **172732-66-0 172732-66-0D**, derivs. **172732-67-1 172732-67-1D**, derivs. **172732-68-2 172732-68-2D**, derivs. **172732-69-3 172732-69-3D**, derivs. **172732-70-6 172732-70-6D**, derivs. **172732-71-7 172732-71-7D**, derivs. **172732-72-8 172732-72-8D**, derivs. 172732-73-9 172732-73-9D, derivs. 172732-74-0 172732-74-0D, derivs. 172733-08-3 172733-42-5 207340-63-4 207340-64-5 207340-65-6 207340-67-8 207340-68-9 207340-69-0 207340-70-3 207340-71-4 207340-72-5 207340-73-6 215160-61-5 245756-90-5 245757-22-6 245757-60-2 245757-62-4 245757-66-8 245757-68-0 245757-70-4 245757-72-6 352352-73-9 352352-74-0 352352-75-1 352352-76-2, Indolizine-1-acetamide 352352-77-3, Indolizine-1-acetic acid hydrazide 352352-78-4 352352-79-5 352352-80-8 352352-80-8D, derivs. 359841-74-0 359841-74-0D, derivs.
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

IT 9001-84-7, Phospholipase A2
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(secretory phospholipase A2 inhibitors for treatment of renal dysfunction)

L108 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:565004 CAPLUS
DOCUMENT NUMBER: 135:152715
TITLE: Secretory phospholipase A2 inhibitors for the

treatment of inflammation
INVENTOR(S): Fleisch, Jerome Herbert; Macias, William Louis
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 200 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055108	A2	20010802	WO 2001-US11	20010116

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-177907 P 20000125
OTHER SOURCE(S): MARPAT 135:152715

AB Title inhibitors for the treatment of inflammation (no data) comprise indoleglyoxamides, carbazoles, etc.

IT Anti-inflammatory agents
(secretory phospholipase A2 inhibitors for the treatment of inflammation)

IT 133876-97-8, Secretory phospholipase A2
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(mediated disorders; treatment; secretory phospholipase A2 inhibitors for the treatment of inflammation)

IT **172732-68-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(secretory phospholipase A2 inhibitors for the treatment of inflammation)

IT 86-74-8, Carbazole 103-81-1, Benzeneacetamide 109-97-7, Pyrrole 288-13-1, Pyrazole 879-37-8, Indole-3-acetamide 942-01-8 2243-81-4, Naphthylacetamide 5548-10-7, Indole-3-glyoxamide 7505-92-2 19402-87-0, 9-Benzylcarbazole 39597-63-2, Indole-1-acetamide 166251-27-0, Indene-1-acetamide **172732-60-4 172732-61-5 172732-62-6 172732-63-7 172732-64-8 172732-65-9 172732-66-0 172732-67-1 172732-69-3 172732-70-6 172732-71-7 172732-72-8** 172732-73-9 172733-08-3 172733-42-5 207340-63-4 207340-64-5 207340-65-6 207340-67-8 207340-68-9 207340-69-0 207340-70-3 207340-72-5 207340-73-6 215160-61-5 220862-20-4 245757-22-6 245757-61-3 245757-62-4 245757-67-9 245757-68-0 245757-71-5 245757-72-6 352352-73-9 352352-74-0 352352-75-1 352352-76-2, 1-Indolizineacetamide 352352-77-3 352352-78-4 352352-79-5 352352-80-8 352352-81-9
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(secretory phospholipase A2 inhibitors for the treatment of inflammation)

IT 100-39-0, Benzyl bromide 5292-43-3, tert-Butyl bromoacetate

104863-65-2, N-Methoxy-N-methylpropanamide 164082-77-3, N-tert-Butoxycarbonyl-3-methoxy-2-methylaniline
RL: RCT (Reactant)
(secretory phospholipase A2 inhibitors for the treatment of inflammation)

IT 164082-78-4P, 1-[2-(tert-Butoxycarbonylamino)-6-methoxyphenyl]-2-butanone 164082-79-5P, 2-Ethyl-4-methoxyindole 164082-80-8P, 2-Ethyl-4-methoxy-1-(phenylmethyl)-1H-indole 172733-06-1P, 2-Ethyl-4-hydroxy-1-(phenylmethyl)-1H-indole 220862-18-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(secretory phospholipase A2 inhibitors for the treatment of inflammation)

IT 220862-19-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(secretory phospholipase A2 inhibitors for the treatment of inflammation)

L108 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:507563 CAPLUS
DOCUMENT NUMBER: 135:87174
TITLE: Combination therapy using a neutrophil elastase inhibitor and an secretory phospholipase A2 inhibitor for the treatment of inflammatory and respiratory diseases
INVENTOR(S): Macias, William Louis
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 263 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049323	A1	20010712	WO 2000-US34262	20001222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-174723 P 20000106
OTHER SOURCE(S): MARPAT 135:87174

AB A pharmaceutical compn. for the treatment of an inflammatory disease or a respiratory disease in mammals comprises, as active ingredients, a neutrophil elastase inhibitor and an sPLA2 inhibitor. Prepn. of [(3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indole-4-yl)oxy]acetic acid is described.

IT Drug delivery systems
(aerosols; neutrophil elastase inhibitor-secretory phospholipase A2 inhibitor combination therapy for inflammatory and respiratory diseases)

IT Drug delivery systems
(capsules; neutrophil elastase inhibitor-secretory phospholipase A2 inhibitor combination therapy for inflammatory and respiratory

diseases)
IT Respiratory tract
(disease; neutrophil elastase inhibitor-secretory phospholipase A2 inhibitor combination therapy for inflammatory and respiratory diseases)
IT Drug delivery systems
(injections, i.v.; neutrophil elastase inhibitor-secretory phospholipase A2 inhibitor combination therapy for inflammatory and respiratory diseases)
IT Anti-inflammatory agents
Drug delivery systems
(neutrophil elastase inhibitor-secretory phospholipase A2 inhibitor combination therapy for inflammatory and respiratory diseases)
IT Drug delivery systems
(parenterals; neutrophil elastase inhibitor-secretory phospholipase A2 inhibitor combination therapy for inflammatory and respiratory diseases)
IT Drug delivery systems
(prodrugs; neutrophil elastase inhibitor-secretory phospholipase A2 inhibitor combination therapy for inflammatory and respiratory diseases)
IT Drug delivery systems
(suppositories; neutrophil elastase inhibitor-secretory phospholipase A2 inhibitor combination therapy for inflammatory and respiratory diseases)
IT Drug delivery systems
(suspensions; neutrophil elastase inhibitor-secretory phospholipase A2 inhibitor combination therapy for inflammatory and respiratory diseases)
IT Drug delivery systems
(tablets; neutrophil elastase inhibitor-secretory phospholipase A2 inhibitor combination therapy for inflammatory and respiratory diseases)
IT 127373-60-8 127373-61-9 127373-66-4 127373-66-4D, prodrug derivs.
127373-68-6 127373-69-7 127373-75-5 127373-78-8 127373-83-5
127373-90-4 127373-93-7 127373-95-9 **172732-60-4**
172732-60-4D, prodrug derivs. **172732-61-5**
172732-61-5D, prodrug derivs. **172732-62-6**
172732-62-6D, prodrug derivs. **172732-63-7**
172732-63-7D, prodrug derivs. **172732-64-8**
172732-64-8D, prodrug derivs. **172732-65-9**
172732-65-9D, prodrug derivs. **172732-66-0**
172732-66-0D, prodrug derivs. **172732-67-1**
172732-67-1D, prodrug derivs. **172732-68-2**
172732-68-2D, prodrug derivs. **172732-69-3**
172732-69-3D, prodrug derivs. **172732-70-6**
172732-70-6D, prodrug derivs. **172732-71-7**
172732-71-7D, prodrug derivs. **172732-72-8**
172732-72-8D, prodrug derivs. 172732-73-9 172732-73-9D, prodrug derivs. 207340-66-7 207340-66-7D, isomers and prodrug derivs. 207340-74-7 207340-74-7D, isomers and prodrug derivs. 207340-75-8 207340-75-8D, isomers and prodrug derivs. 207340-77-0 207340-77-0D, isomers and prodrug derivs. 207340-78-1 207340-78-1D, isomers and prodrug derivs. 207340-81-6 207340-81-6D, isomers and prodrug derivs. 207340-82-7 207340-82-7D, isomers and prodrug derivs. 207340-85-0 207340-85-0D, isomers and prodrug derivs. 207340-86-1 207340-86-1D, isomers and prodrug derivs. 220862-20-4 220862-20-4D, prodrug derivs. 220862-21-5 220862-21-5D, isomers and prodrug derivs. 220862-22-6 220862-22-6D, isomers and prodrug derivs. 220862-23-7 220862-23-7D, isomers and prodrug derivs. 220862-24-8 220862-24-8D, isomers and

prodrug derivs. 220862-25-9 220862-25-9D, isomers and prodrug derivs. 220862-26-0 220862-26-0D, isomers and prodrug derivs. 220862-27-1 220862-27-1D, isomers and prodrug derivs. 220862-28-2 220862-28-2D, isomers and prodrug derivs. 220862-30-6 220862-30-6D, isomers and prodrug derivs. 220862-31-7 220862-31-7D, isomers and prodrug derivs. 220862-32-8 220862-32-8D, isomers and prodrug derivs. 220862-33-9 220862-33-9D, isomers and prodrug derivs. 220862-34-0 220862-34-0D, isomers and prodrug derivs. 220862-35-1 220862-35-1D, isomers and prodrug derivs. 220862-36-2 220862-36-2D, isomers and prodrug derivs. 220862-37-3 220862-37-3D, isomers and prodrug derivs. 220862-38-4 220862-38-4D, isomers and prodrug derivs. 220862-39-5 220862-39-5D, isomers and prodrug derivs. 220862-40-8 220862-40-8D, isomers and prodrug derivs. 220862-41-9 220862-41-9D, isomers and prodrug derivs. 220862-42-0 220862-42-0D, isomers and prodrug derivs. 220862-43-1 220862-43-1D, isomers and prodrug derivs. 220862-44-2 220862-44-2D, isomers and prodrug derivs. 220862-45-3 220862-45-3D, isomers and prodrug derivs. 220862-46-4 220862-46-4D, isomers and prodrug derivs. 220862-47-5 220862-47-5D, isomers and prodrug derivs. 220862-48-6 220862-48-6D, isomers and prodrug derivs. 220862-49-7 220862-49-7D, isomers and prodrug derivs. 220862-50-0 220862-50-0D, isomers and prodrug derivs. 220862-51-1 220862-51-1D, isomers and prodrug derivs. 220862-54-4 220862-54-4D, isomers and prodrug derivs. 220862-55-5 220862-55-5D, isomers and prodrug derivs. 220862-56-6 220862-56-6D, isomers and prodrug derivs. 220862-57-7 220862-57-7D, isomers and prodrug derivs. 220862-58-8 220862-58-8D, isomers and prodrug derivs. 220862-59-9 220862-59-9D, isomers and prodrug derivs. 220862-60-2 220862-60-2D, isomers and prodrug derivs. 220862-61-3 220862-61-3D, isomers and prodrug derivs. 220862-62-4 220862-62-4D, isomers and prodrug derivs. 220862-63-5 220862-63-5D, isomers and prodrug derivs. 220862-64-6 220862-64-6D, isomers and prodrug derivs. 220862-65-7 220862-65-7D, isomers and prodrug derivs. 220862-66-8 220862-66-8D, isomers and prodrug derivs. 220862-68-0 220862-68-0D, isomers and prodrug derivs. 220862-70-4 220862-70-4D, isomers and prodrug derivs. 220862-72-6 220862-74-8 220862-74-8D, isomers and prodrug derivs. 220862-76-0 220862-76-0D, isomers and prodrug derivs. 220862-84-0 225653-40-7 225653-40-7D, isomers and prodrug derivs.
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neutrophil elastase inhibitor-secretory phospholipase A2 inhibitor combination therapy for inflammatory and respiratory diseases)

IT 9004-06-2, Neutrophil elastase 133876-97-8, Secretory phospholipase A2
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(neutrophil elastase inhibitor-secretory phospholipase A2 inhibitor combination therapy for inflammatory and respiratory diseases)

IT 164082-78-4P 164082-79-5P, 2-Ethyl-4-methoxy-1H-indole 164082-80-8P 172733-06-1P 172733-07-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction; neutrophil elastase inhibitor-secretory phospholipase A2 inhibitor combination therapy for inflammatory and respiratory diseases)

IT 79-37-8, Oxalyl chloride 96-32-2, Methyl bromoacetate 100-39-0, Benzyl bromide 598-30-1, sec-Butyllithium 104863-65-2, N-Methoxy-N-methylpropanamide 164082-77-3
RL: RCT (Reactant)
(reaction; neutrophil elastase inhibitor-secretory phospholipase A2 inhibitor combination therapy for inflammatory and respiratory diseases)

REFERENCE COUNT: 6

REFERENCE(S): (1) Furuno, T; INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 1997, V112(3), P262 CAPLUS
(3) Lilly Co Eli; EP 0675110 A 1995 CAPLUS
(4) Lilly Co Eli; EP 0839806 A 1998 CAPLUS
(5) Micetich, R; WO 0015207 A 2000 CAPLUS
(6) Okegawa, T; US 5403850 A 1995 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:466526 CAPLUS
DOCUMENT NUMBER: 135:170901
TITLE: Characterization of pharmaceutical compounds and related substances by using HPLC FTICR-MS and tandem mass spectrometry
AUTHOR(S): Winger, Brian E.; Kemp, Craig A. J.
CORPORATE SOURCE: Eli Lilly and Co., Indianapolis, IN, 46285, USA
SOURCE: Am. Pharm. Rev. (2001), 4(2), 55-56,58,60,62-63
CODEN: APHRFS; ISSN: 1099-8012
PUBLISHER: Russell Publishing L.L.C
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A method combining HPLC with FTICR-MS for the anal. of drug stress degrdn.
products to improve identification ability of unknown compds. was presented. The exact mass information obtained in an online expt. drastically reduced the need for isolating and purifying substantial quantities of material. FTICR-MS is a vital tool for the anal. chemist involved with research and development in the pharmaceutical industry.
IT HPLC
Tandem mass spectrometry
(characterization of pharmaceutical compds. and related substances by using HPLC FTICR-MS and tandem mass spectrometry)
IT 150399-23-8, LY 231514 **172732-68-2**, LY 315920 354123-52-7
RL: ANT (Analyte); ANST (Analytical study)
(characterization of pharmaceutical compds. and related substances by using HPLC FTICR-MS and tandem mass spectrometry)
REFERENCE COUNT: 20
REFERENCE(S): (3) Cody, R; Anal Chem 1982, V54, P96 CAPLUS
(5) Comisarow, M; Chem Phys Lett 1974, V25, P282 CAPLUS
(7) Fenn, J; Mass Spectrom Rev 1990, V9, P37 CAPLUS
(8) Gauthier, J; Anal Chim Acta 1991, V246, P211 CAPLUS
(9) Haskins, N; Rapid Commun Mass Spectrom 1995, V9, P1027 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:453013 CAPLUS
DOCUMENT NUMBER: 135:46087
TITLE: Preparation of indoles as drug intermediates
INVENTOR(S): Sawyer, Jason Scott
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044185	A1	20010621	WO 2000-US32447	20001211

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-171218 P 19991216
OTHER SOURCE(S): CASREACT 135:46087; MARPAT 135:46087
AB HZR2 [R2 = H, OH, NH2, alkyl, aryl, etc.; Z = (un)substituted 1,2-indolediyl] were prepd. by cyclization of R2CH:CR3Z1NO2 [R3 = H, halo, alkyl, alkoxy, etc.; Z1 = (un)substituted 1,2-phenylene] in the presence of CO and a catalyst.
IT 16855-08-6P, 2-Hydroxy-6-nitrobenzaldehyde 345232-52-2P 345232-53-3P 345232-54-4P 345232-55-5P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of indoles as drug intermediates)
IT 164082-79-5P **172732-68-2P** 172733-07-2P 172733-08-3P 172733-42-5P 249730-11-8P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of indoles as drug intermediates)
IT 620-05-3, Benzyl iodide 6228-47-3, Propyltriphenylphosphonium bromide 19689-88-4, 2-Methoxy-6-nitrobenzaldehyde
RL: RCT (Reactant)
(prepn. of indoles as drug intermediates)
REFERENCE COUNT: 16
REFERENCE(S):
(1) Bach, N; US 5654326 A 1997 CAPLUS
(2) Denney, M; WO 9956752 A 1999 CAPLUS
(3) Draheim, S; Journal of Medicinal Chemistry 1996, V39(26), P5159 CAPLUS
(4) Kawase, M; Journal of Heterocyclic Chemistry 1987, V24(6), P1499 CAPLUS
(5) Lilly Co Eli; WO 9842343 A 1998 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:453012 CAPLUS
DOCUMENT NUMBER: 135:46086
TITLE: Preparation of indoles as drug intermediates
INVENTOR(S): Martinelli, Michael John; Sawyer, Jason Scott
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044184	A1	20010621	WO 2000-US32444	20001211

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-171230 P 19991216
OTHER SOURCE(S): MARPAT 135:46086
AB R1ZR2 [R1 = H, alkyl, aryl, alkanoyl, aroyl, etc.; R2 = H, OH, NH2, alkyl, alkoxy, aryl, alkanoyl, aroyl, etc.; Z = (un)substituted indole-1,2-diyl] were prepd. by cyclization of R2CONR1Z1CHRR3 [R3 = trisubstituted P; Z1 = (un)substituted 1,2-phenylene].
IT 19689-86-2P 19689-87-3P 164082-80-8P 177531-95-2P 345232-14-6P 345232-15-7P 345232-16-8P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of indoles as drug intermediates)
IT 164082-79-5P **172732-68-2P** 172733-08-3P 172733-42-5P 249730-11-8P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of indoles as drug intermediates)
IT 79-03-8, Propionyl chloride 4837-88-1, 2-Methyl-3-nitroanisole
RL: RCT (Reactant)
(prepn. of indoles as drug intermediates)
REFERENCE COUNT: 7
REFERENCE(S):
(1) Ashton, M; US 4493843 A 1985 CAPLUS
(2) Bach, N; US 5654326 A 1997 CAPLUS
(3) Blechert, S; HELVETICA CHIMICA ACTA 1985, V68, P1835 CAPLUS
(4) Cirrincione, G; IL FARMACO 1995, V50(12), P849 CAPLUS
(6) Le Corre, M; TETRAHEDRON 1985, V41(22), P5313 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:453010 CAPLUS
DOCUMENT NUMBER: 135:46085
TITLE: Preparation of indoles as drug intermediates
INVENTOR(S): Beight, Douglas Wade; Sawyer, Jason Scott
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044182	A2	20010621	WO 2000-US32446	20001211

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 1999-171236 P 19991216
OTHER SOURCE(S): MARPAT 135:46085
AB R1ZR2 [R1 = H, alkyl, aryl, alkanoyl, aroyl, etc.; R2 = H, OH, NH2, alkyl,
alkoxy, aryl, alkanoyl, aroyl, etc.; Z = (un)substituted 1,2-indolediyl]
were prepd. by cyclization of R2COCHR3Z1NRR1 [R = amino-protective group;
R3 = H, halo, alkyl, alkoxy, etc.; Z1 = (un)substituted 1,2-phenylene].
IT 56619-93-3P 345232-24-8P 345232-25-9P 345232-26-0P 345232-27-1P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic
preparation); PREP (Preparation)
(prepn. of indoles as drug intermediates)
IT 164082-79-5P, 2-Ethyl-4-methoxy-1H-indole **172732-68-2P**
172733-08-3P 172733-42-5P 249730-11-8P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
(Preparation)
(prepn. of indoles as drug intermediates)
IT 106-88-7, 1,2-Epoxybutane 536-90-3 3282-30-2, Trimethylacetyl chloride
RL: RCT (Reactant)
(prepn. of indoles as drug intermediates)

L108 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:283786 CAPLUS
DOCUMENT NUMBER: 134:290409
TITLE: Preparation of V type and/or X type sPLA2 inhibitors
INVENTOR(S): Ono, Takashi; Ueno, Masahiko; Hanasaki, Kohji
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001026653	A1	20010419	WO 2000-JP7024	20001010

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: JP 1999-293273 A 19991015
OTHER SOURCE(S): MARPAT 134:290409
GI



I



II

AB V type and/or X type sPLA2 inhibitors which contain as the active ingredient compds. represented by general formulas [I; X = CHR2, N; X1 = C, N; X2 = C, N; Y = R6; Z = R7; YZ = C(CONH2):CHCH:CH; R1 = OH, NHSO2C6H5; R2, R3, R4 independently = H, CH3, C6H5, F; ; R5 = 4-C6H5C6H4CH2, C6H5CH2, cyclohexylmethyl, 2-cyclopentylphenyl; R6 = H, C1-3 alkyl; R7 = COCONH2, CH2CONH2; dotted bond = single, double], prodrugs thereof, and pharmaceutically acceptable salts of the same or solvates of the same are prepd. as V type and/or X type sPLA2 inhibitors. Thus, the title compd. II was prepd. and tested for X type sPLA2 inhibition with an IC50 of 3 nM.

IT Drug delivery systems
(prodrugs; prepn. of V type and/or X type sPLA2 inhibitors)

IT **172732-68-2P** 207340-86-1P 220862-34-0P 220862-37-3P
220862-61-3P 220862-64-6P 245756-91-6P 245756-99-4P 245757-15-7P
245757-35-1P 245757-51-1P 258262-50-9P 324519-86-0P 334542-69-7P
334542-70-0P 334542-71-1P 334542-72-2P 334542-73-3P 334542-74-4P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of V type and/or X type sPLA2 inhibitors)

IT 9001-84-7, Phospholipase A2
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(prepn. of V type and/or X type sPLA2 inhibitors)

REFERENCE COUNT: 64
REFERENCE(S):
(1) Eli Lilly And Company; JP 07285933 A CAPLUS
(2) Eli Lilly And Company; EP 1043991 A1 CAPLUS
(6) Eli Lilly And Company; CN 1098714 A CAPLUS
(7) Eli Lilly And Company; CN 1098715 A CAPLUS
(8) Eli Lilly And Company; CN 1114310 A CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:227213 CAPLUS
DOCUMENT NUMBER: 135:40418
TITLE: Protein-based alignment in 3D QSAR of 26 indole inhibitors of human pancreatic phospholipase A2

AUTHOR(S): Pintore, Marco; Bernard, Philippe; Berthon, Jean-Yves;
Chretien, Jacques R.
CORPORATE SOURCE: Laboratory of Chemometrics & BioInformatics, Faculty of Sciences, University of Orleans, Orleans, 45067, Fr.
SOURCE: Eur. J. Med. Chem. (2001), 36(1), 21-30
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB An automated docking procedure was applied on a series of 26 reversible and competitive indole inhibitors of human pancreatic phospholipase A2 (hp-PLA2). X-ray data of this enzyme are not available and the structure was then reconstructed exploiting its protein sequence and the crystallog.
data of a bovine pancreatic source. The docking data were used to build a
three-dimensional quant. structure-activity relation (3D QSAR) model, established using the comparative mol. field anal. (CoMFA) method. This model, joined to the previous one developed for the indole inhibitors of human non-pancreatic secretory phospholipase A2 (hnps-PLA2), an enzyme involved in inflammation processes, will allow for the selection of new strong anti-inflammatory drugs with negligible side effects, at least at the level of hp-PLA2.
IT Protein sequences
(alignment; protein-based alignment in 3D QSAR of 26 indole inhibitors of human pancreatic phospholipase A2)
IT QSAR (structure-activity relationship)
(comparative mol. field anal.; protein-based alignment in 3D QSAR of 26
indole inhibitors of human pancreatic phospholipase A2)
IT Anti-inflammatory agents
QSAR (structure-activity relationship)
(protein-based alignment in 3D QSAR of 26 indole inhibitors of human pancreatic phospholipase A2)
IT 164083-80-1 164083-84-5 164083-86-7 164083-90-3 164083-96-9
164084-07-5 164084-10-0 164084-13-3 164084-42-8 164084-57-5
164084-59-7 164084-60-0 164084-61-1 **172732-60-4**
172732-67-1 **172732-69-3** 185298-64-0 185501-30-8
185501-54-6 344612-30-2 344612-31-3 344612-32-4 344612-33-5
344612-34-6 344612-35-7
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(protein-based alignment in 3D QSAR of 26 indole inhibitors of human pancreatic phospholipase A2)
IT 9001-84-7, Phospholipase A2 133876-97-8, Secretory phospholipase A2
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(protein-based alignment in 3D QSAR of 26 indole inhibitors of human pancreatic phospholipase A2)
REFERENCE COUNT: 43
REFERENCE(S): (1) Arni, R; Toxicon 1996, V34, P827 CAPLUS
(2) Bereziat, G; J Lipid Mediators 1990, V2, P159 CAPLUS
(5) Bromidge, S; J Med Chem 1998, V41, P1598 CAPLUS
(6) Christensen, I; Drug Des Discov 1993, V10, P101 CAPLUS
(7) Clark, J; Proc Natl Acad Sci 1990, V87, P7708 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:227212 CAPLUS
DOCUMENT NUMBER: 135:40417
TITLE: A molecular modeling and 3D QSAR study of a large series of indole inhibitors of human non-pancreatic secretory phospholipase A2
AUTHOR(S): Bernard, Philippe; Pintore, Marco; Berthon, Jean-Yves; Chretien, Jacques R.
CORPORATE SOURCE: Laboratory of Chemometrics and BioInformatics, University of Orleans, Orleans, 45067, Fr.
SOURCE: Eur. J. Med. Chem. (2001), 36(1), 1-19
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Automated docking allowing protein-based alignment was performed for a series of 188 indole inhibitors of the human non-pancreatic secretory phospholipase A2 (hnps-PLA2). All the substituted indoles were docked to the crystal structure of hnps-PLA2 and a three-dimensional QSAR model was then established using the CoMFA method. The set of 188 compds. was divided into two subsets, the first one constituting the training set (126 compds.), while the second constituted the test set (62 compds.). The established CoMFA model derived from the training set was then applied to the test set. A good correlation between predicted and exptl. activity data allows to validate the 3D QSAR model. A second and global 3D QSAR including all the compds. was established, allowing the creation of the hnps-PLA2 pharmacophore.

IT Crystal structure
Molecular modeling
Pharmacophores
(a mol. modeling and 3D QSAR study of a large series of indole inhibitors of human non-pancreatic secretory phospholipase A2)

IT QSAR (structure-activity relationship)
(comparative mol. field anal., CoMFA; a mol. modeling and 3D QSAR study of a large series of indole inhibitors of human non-pancreatic secretory phospholipase A2)

IT 1568-30-5 57846-28-3 59283-35-1 93871-13-7 93879-42-6 97077-43-5
102174-35-6 163687-72-7 163687-73-8 163687-78-3 163687-84-1
163687-96-5 163687-99-8 163734-44-9 163734-45-0 163734-46-1
163734-51-8 163734-55-2 163734-57-4 163734-58-5 163734-59-6
163734-60-9 163734-61-0 163734-62-1 163734-65-4 163734-68-7
163734-71-2 163734-72-3 163734-75-6 163734-76-7 163734-77-8
163734-78-9 163734-82-5 163734-84-7 164082-81-9 164082-82-0
164082-83-1 164082-97-7 164083-06-1 164083-24-3 164083-29-8
164083-78-7 164083-79-8 164083-80-1 164083-83-4 164083-84-5
164083-85-6 164083-87-8 164083-88-9 164083-91-4 164083-96-9
164083-97-0 164083-98-1 164083-99-2 164084-00-8 164084-01-9
164084-02-0 164084-04-2 164084-05-3 164084-06-4 164084-07-5
164084-10-0 164084-11-1 164084-12-2 164084-13-3 164084-24-6
164084-25-7 164084-28-0 164084-29-1 164084-30-4 164084-31-5
164084-32-6 164084-34-8 164084-36-0 164084-37-1 164084-39-3
164084-41-7 164084-42-8 164084-43-9 164084-44-0 164084-47-3
164084-48-4 164084-49-5 164084-50-8 164084-51-9 164084-52-0
164084-53-1 164084-54-2 164084-55-3 164084-57-5 164084-58-6
164084-59-7 164084-60-0 164084-61-1 164084-62-2 164084-64-4

164084-65-5 164123-34-6 165905-06-6 **172732-60-4**
172732-62-6 172732-63-7 172732-64-8
172732-65-9 172732-66-0 172732-67-1
172732-68-2 172732-69-3 172732-70-6
172732-71-7 172732-72-8 172732-73-9 172732-74-0
172732-75-1 172732-76-2 172733-31-2 172733-37-8 185063-66-5
185063-67-6 185063-68-7 185063-70-1 185063-71-2 185063-72-3
185063-73-4 185063-74-5 185063-75-6 185063-76-7 185063-77-8
185063-78-9 185063-79-0 185063-81-4 185064-11-3 185298-58-2
185298-62-8 185298-63-9 185298-64-0 185298-65-1 185298-66-2
185298-68-4 185298-69-5 185298-72-0 185298-75-3 185298-76-4
185298-83-3 185298-84-4 185298-85-5 185298-90-2 185298-91-3
185299-07-4 185299-08-5 185500-88-3 185500-89-4 185500-98-5
185501-06-8 185501-13-7 185501-15-9 185501-17-1 185501-21-7
185501-25-1 185501-30-8 185501-53-5 185501-54-6 185501-55-7
185501-56-8 185501-71-7 185501-76-2 185501-78-4 185501-79-5
185501-80-8 185501-84-2 185501-85-3 185501-89-7 263910-31-2
344741-23-7 344741-24-8 344741-25-9 344741-26-0 344741-27-1
344741-28-2 344741-29-3 344741-30-6 344741-31-7 344741-32-8
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
(a mol. modeling and 3D QSAR study of a large series of indole inhibitors of human non-pancreatic secretory phospholipase A2)

IT 133876-97-8, Secretory phospholipase A2
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(a mol. modeling and 3D QSAR study of a large series of indole inhibitors of human non-pancreatic secretory phospholipase A2)

REFERENCE COUNT: 57
REFERENCE(S):
(5) Baba, A; J Med Chem 1996, V39, P5176 CAPLUS
(6) Bennion, C; J Med Chem 1992, V35, P2939 CAPLUS
(7) Bernard, P; Analusis 1998, V26, P333 CAPLUS
(8) Bernard, P; Curr Opin Drug Disc Devel 1999, V2, P213 CAPLUS
(9) Bernard, P; J Comput-Aided Mol Des 1999, V13, P355 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:146404 CAPLUS
DOCUMENT NUMBER: 134:347867
TITLE: An update on inhibitors of human 14 kDa Type II s-PLA2 in development
AUTHOR(S): Springer, Dane M.
CORPORATE SOURCE: Anti-infective Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, 06492, USA
SOURCE: Curr. Pharm. Des. (2001), 7(3), 181-198
CODEN: CPDEFP; ISSN: 1381-6128
PUBLISHER: Bentham Science Publishers
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 101 refs. Recent progress in the development of inhibitors of human Type II s-PLA2 as potential anti-inflammatory agents is presented. While many companies have curtailed their efforts in the PLA2 area, Eli Lilly and Shionogi are continuing to advance LY-315920 (S-5920) as a potential treatment for sepsis and other diseases that have an inflammatory component. The Lilly developmental effort leading to LY-315920 is extensively reviewed, as well as the current status of other

small mol. wt. inhibitors of Type II s-PLA2 that have been reported to be in late-stage development.

IT Anti-inflammatory agents
Drug design
(update on inhibitors of human 14 kDa Type II s-PLA2 in development)

IT 9001-84-7, Phospholipase A2
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(14 kDa Type II s-; update on inhibitors of human 14 kDa Type II s-PLA2
in development)

IT **172732-68-2**, LY-315920
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(update on inhibitors of human 14 kDa Type II s-PLA2 in development)

REFERENCE COUNT: 112
REFERENCE(S): (1) Al Moutaery, A; Digestion 1997, V58, P129 CAPLUS
(4) Arita, H; J Biol Chem 1991, V266, P19139 CAPLUS
(5) Atsumi, G; J Biol Chem 1998, V273, P13870 CAPLUS
(6) Axelrod, J; Chem Senses 1989, V1, P1 CAPLUS
(10) Bradley, P; J Invest Derm 1982, V78, P206 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:769082 CAPLUS
DOCUMENT NUMBER: 133:321890
TITLE: Preparation of morpholinoethyl ester derivative of an indole sPLA2 inhibitor
INVENTOR(S): Sawyer, Jason Scott; Morin, John Michael, Jr.; Beight, Douglas Wade; Sall, Daniel Jon; Buben, John Andrew
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6140327	A	20001031	US 1999-310563	19990512
WO 2000069818	A1	20001123	WO 2000-US6704	20000508

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-310563 A 19990512

AB ((3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid morpholinoethyl ester was prepd. Its use as a highly bioavailable indole compd. for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock was reported.

IT 172732-80-8 249730-08-3 249730-10-7
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(prepn. of morpholinoethyl ester deriv. of an indole sPLA2 inhibitor)